Antibody drug conjugate ,historical and future overview | ||||
| Sohag Medical Journal | ||||
| Volume 27, Issue 2, 2023, Page 59-75 PDF (1.18 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/smj.2023.199323.1376 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Sahar Noureldeen Hammam 
| ||||
| Lecturer of Clinical Oncology ,Faculty of medicine ,Sohag University | ||||
| Abstract | ||||
| Antibody-drug Conjugates (ADCs)which are composed of a monoclonal antibody (MoAb), a linker, and a payload; is a type of highly targeted biopharmaceutical drug that conjugate “monoclonal antibodies’ that are specific to antigens present on the surface of particular tumour cells with highly effective anti-cancer agents, all of which are linked to one another via a chemical linker. Recent advances in biotechnology have resulted in significant leaps in therapeutic potential for (ADCs). These improvements have been made possible by ADCs. This review aims to demonstrate the concept of ADC and its based chemotherapies that are used in management of different kinds of cancer in the last few years. This review could be represents an integrated reference for many researchers and those interested in the field of cancer treatments, as it summarizes all antibody-based drugs, their effectiveness, and the types of cancer they treat, making it easier for researchers to view all antibody-based drugs. | ||||
| Keywords | ||||
| Chemotherapy; Anti-body drug conjugate; Cancer therapy; payload | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 115 PDF Download: 92 |
||||
